This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the drug label approved by the MFDS in Korea.
Study Type
OBSERVATIONAL
Enrollment
1,758
Participants will receive atezolizumab as per the local label and standard of care at physician's discretion.
Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
Time frame: Approximately 6 years
Percentage of Participants With Complete Response (CR) Assessed per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Time frame: Approximately 6 years
Percentage of Participants With Partial Response (PR) Assessed per RECIST 1.1
Time frame: Approximately 6 years
Percentage of Participants With Stable Disease (SD) Assessed per RECIST 1.1
Time frame: Approximately 6 years
Percentage of Participants With Progressive Disease (PD) Assessed per RECIST 1.1
Time frame: Approximately 6 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Dongnam Inst.of Radiological & Medical Sciences
Busan, South Korea
Inje University Busan Paik Hospital
Busan, South Korea
Inje university Haeundae Paik Hospital
Busan, South Korea
Dong-A University Hospital
Busan, South Korea
Pusan National University Hospital
Busan, South Korea
Kosin University Gospel Hospital
Busan, South Korea
Donga Uni Medical Center; Pulmonary
Busan, South Korea
Pusan University Hospital
Busan, South Korea
Pusan University Hospital; Hemato-oncology
Busan, South Korea
Kyungpook National University Medical Center
Daegu, South Korea
...and 46 more locations